601607 上海医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入215,072,2302.60%275,250,935260,295,089231,981,300215,824,259
减:营业总成本209,405,9792.94%267,676,307253,008,864224,907,251209,641,475
    其中:营业成本192,652,5373.33%244,619,261228,966,947201,494,923187,281,149
               财务费用1,114,865-2.99%1,480,9121,485,7581,313,1921,245,369
               资产减值损失(789,412)1,119.12%(614,374)(561,277)(331,471)(140,441)
公允价值变动收益113,140-20.44%203,854404,731218,738(206,004)
投资收益3,370,052881.11%380,427(68,123)533,1171,811,394
    其中:对联营企业和合营企业的投资收益479,6177.10%521,909129,329526,743789,596
营业利润8,336,76925.01%8,140,7137,667,2359,014,6508,205,486
利润总额8,298,09724.89%8,020,0077,054,2978,808,3538,143,815
减:所得税费用2,311,94842.62%2,149,9951,887,7261,816,3391,869,245
净利润5,986,14919.17%5,870,0115,166,5706,992,0156,274,569
减:非控股权益839,085-13.42%1,317,4831,398,5711,374,8631,181,102
股东净利润5,147,06526.96%4,552,5283,768,0005,617,1525,093,467

市场价值指针
每股收益 (元) *1.39027.52%1.2301.0201.6101.790
每股派息 (元) *0.12050.00%0.3700.4100.6100.420
每股净资产 (元) *20.4366.83%19.33018.50018.13717.367
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容